HPLC method for determination of biologically active epoxy-transformers of treosulfan in human plasma: Pharmacokinetic application

Journal of Pharmaceutical and Biomedical Analysis

Volumn 62, Issue , 2012, Pages 105-113

  Główka, Franciszek K ^a   Romański, Michał ^a   Tezyk, Artur ^a   zaba, Czesław ^a   Wróbel, Tomasz ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Epoxides; Esters; Hematopoietic stem cell transplantation; Optimization; RP HPLC; Validation

Indexed keywords

2,4 DINITROPHENOL; ACETONITRILE; BENZENESULFONIC ACID DERIVATIVE; BUTADIENE DIEPOXIDE; DICHLOROMETHANE; TREOSULFAN; WATER;

ARTICLE; DERIVATIZATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG ISOLATION; DRUG STABILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MASS SPECTROMETRY; PH; PRIORITY JOURNAL; PROTEIN BINDING; TEMPERATURE; ULTRAVIOLET RADIATION;

BUSULFAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MASS SPECTROMETRY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84857138746     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.12.021     Document Type: Article

References (26)

1. Gropp M., Meier W., Hepp H. Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol. Oncol. 1998, 71:94-98.
2. Spieth K., Kaufmann R., Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother. Pharmacol. 2003, 52:377-382.
3. Wachowiak J., Chybicka A., Boruczkowski D., Gorczyńska E., Kałwak K., Leda M., Pieczonka A., Toporski J., Turkiewicz D., Witt M. Intravenous treosulfan in conditioning before allogeneic HSCT from MSD in children with high risk of toxic complications related to conventional preparative regimen. Bone Marrow Transplant. 2002, 30(Suppl. 1):S12.
4. Casper J., Knauf W., Kiefer T., Wolff D., Steiner B., Hammer U., Wegener R., Kleine H.D., Wilhelm S., Knopp A., Hartung G., Dölken G. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004, 103:725-731.
5. Beelen D.W., Trenschel R., Casper J., Freund M., Hilger R.A., Scheulen M.E., Basara N., Fauser A.A., Hertenstein B., Mylius H.A., Baumgart J., Pichlmeier U., Hahn J.R., Holler E. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant. 2005, 35:233-241.
6. Cutting R., Mirelman A., Vora A. Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation. Br. J. Haematol. 2008, 143:748-751.
7. Boobis A., Rawlins M., Thomas S., Wilkins M. Treosulfan. The Drugs 1999, T161-T162. Churchill Livingstone, Edinburgh. second ed. C. Dollery (Ed.).
8. Feit P.W., Rastrup-Andersen N., Matagne R. Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate. J. Med. Chem. 1970, 13:1173-1175.
9. Hartley J.A., O'Hare C.C., Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan. Br. J. Cancer 1999, 79:264-266.
10. Matagne R. Activity of l-threitol-1,4-bismethanesulfonate on barley chromosomes in relation to chemical transformation during treatment. Mutat. Res. 1967, 4:621-630.
11. Główka F.K., Karaźniewicz-Łada M., Grund G., Wachowiak J. Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetics studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation. J. Chromatogr. B 2007, 850:569-574.
12. Hilger R.A., Harstrick A., Eberhardt W., Oberhoff C., Skorzec M., Baumgart J., Seeber S., Scheulen M.E. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 1998, 42:99-104.
13. Cheng X., Ruth J.A. A simplified methodology for quantitation of butadiene metabolites. Application to the study of 1,3-butadiene metabolism by rat liver microsomes. Drug Metab. Dispos. 1993, 21:121-124.
14. Himmelstein M.W., Turner M.J., Asgharian B., Bond J.A. Comparison of blood concentrations of 1,3-butadiene and butadiene epoxides in mice and rats exposed to 1,3-butadiene by inhalation. Carcinogenesis 1994, 15:1479-1486.
15. Bechtold W.E., Strunk M.R., Thornton-Manning J.R., Henderson R.F. Analysis of butadiene, butadiene monoxide and butadiene dioxide in blood by gas chromatography/gas chromatography/mass spectroscopy. Chem. Res. Toxicol. 1995, 8:182-187.
16. Krause J.R., Elfarra A.A. Oxidation of butadiene monoxide to meso- and (±)-diepoxybutane by cDNA-expressed human cytochrome P450s and by mousse, rat, and human liver microsomes: evidence for preferential hydratation of meso-diepoxybutane in rat and human liver microsomes. Arch. Biochem. Biophys. 1997, 337:176-184.
17. Dupard-Julien C.L., Kandlakunta B., Uppu R.M. Determination of epoxides by high-performance liquid chromatography following derivatization with N,N-diethyldithiocarbamate. Anal. Bioanal. Chem. 2007, 387:1027-1032.
18. Filser J.G., Hutzler C., Meischner V., Veereshwarayya V., Csanady G.A. Metabolism of 1,3-butadiene to toxicologically relevant metabolites in single-exposed mice and rats. Chem. Biol. Interact. 2007, 166:93-103.
19. Haglund J., Silvari V., Esmans E., Törnqvist M. Cobalamin as an analytical tool for analysis of oxirane metabolites of 1,3-butadiene: development and validation of the method. J. Chromatogr. A 2006, 1119:246-250.
20. Valentine J.L., Boogaard P.J., Sweeney L.M., Turner M.J., Bond J.A., Medinsky M.A. Disposition of butadiene epoxides in Sprague-Dawley rats. Chem. Biol. Interact. 1997, 104:103-115.
21. Thornton-Manning J.R., Dahl A.R., Bechtold W.E., Griffith W.C., Hederson R.F. Disposition of butadiene monoepoxide and butadiene diepoxide in various tissues of rats and mice following a low-level inhalation exposure to 1,3-butadiene. Carcinogenesis 1995, 16:1723-1731.
22. Boogaard P.J., Bond J.A. The role of hydrolysis in the detoxification of 1,2:3,4-diepoxybutane by human, rat, and mouse liver and lung in vitro. Toxicol. Appl. Pharmacol. 1996, 141:617-627.
23. Cech N.B., Krone J.R., Enke C.G. Electrospray ionization detection of inherently nonresponsive epoxides by peptide binding. Rapid Commun. Mass Spectrom. 2001, 15:1040-1044.
24. EMEA Quality guidelines: validation of analytical procedures: text and methodology (ICH Q2). Available from: (last accessed 17 March 2011). http://www.emea.europa.eu/pdfs/human/ich/038195en.pdf.
25. van Damme F., Oomens A.C. Determination of residual free epoxide in polyether polyols by derivatization with diethylammonium N,N-diethyldithiocarbamate and liquid chromatography. J. Chromatogr. A 1995, 696:41-47.
26. Scheulen M.E., Hilger R.A., Oberhoff C., Casper J., Freund M., Josten K.M., Bornhauser M., Ehninger G., Berdel W.E., Baumgart J., Harstrick A., Bojko P., Wolf H.H., Schindler A.E., Seeber S. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin. Cancer Res. 2000, 6:4209-4216.